Hydrea
Hydrea

2.12
For patients managing oncology care, this generic medicine disrupts DNA synthesis to slow the proliferation of abnormal cell populations.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Hydroxyurea
Reference Brand
Hydroxyurea
Product Origin
Generic Alternative
Reference Manufacturer
Bristol-Myers Squibb
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Pain Relief
Product Category
Antineoplastic Agent
Pharmacological Class
Ribonucleotide Reductase Inhibitor
Manufacturer Description
Intended to relieve abnormal cellular proliferation to support clinical remission and target vascular sickle pain crises.
Mechanism of Action
Inhibits ribonucleotide reductase, blocking conversion of ribonucleotides to deoxyribonucleotides to arrest DNA synthesis.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
24 hours
Contraindications
Severe bone marrow suppression, Hypersensitivity to hydroxyurea
Severe Adverse Events
Severe neutropenia — requires immediate medical attention, Cutaneous vasculitis ulcers — requires immediate medical attention
Common Side Effects
Nausea, Vomiting, Mild diarrhea
Uncommon Side Effects
Myelosuppression, Skin hyperpigmentation, Maculopapular rash
Drug Interactions
Didanosine, Stavudine, Live Vaccines
Pregnancy Safety Warnings
TGA Category D: High risk of fetal toxicity. Strictly avoid in pregnancy. Breastfeeding: Contraindicated.
Age Restrictions
Approved for children and adults.
Storage Guidelines
Store below 25°C.
Information related to Hydrea is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
how to order Women's Prescription - Buy Medroxyprogesterone AU